Anti-CD47 & PD-1 Bispecific Antibody (BJZ221) is a research-grade recombinant antibody targeting CD47. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.